scPharmaceuticals Inc. (SCPH) stock gained by 7.34% at last close while the SCPH stock price surges by 2.13% in the after-hours trading session. SC Pharmaceuticals is a biopharmaceutical business specializing in the development and commercialization of medicines that aim to save healthcare expenditures and enhance health outcomes.
>> 7 Top Picks for the Post-Pandemic Economy <<
What is happening?
The FREEDOM-HF trial by SC pharmaceuticals yielded good top-line findings. FREEDOM-HF was a randomized controlled study that looked at the overall and heart failure-related costs of dealing with congestion in severe heart failure patients. Patients were treated with FUROSCIX, SCPH’s experimental medicine, after being discharged from the emergency department, versus a historical-comparative group who received intravenous furosemide in the inpatient hospital setting.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Enrollment was stopped on May 17, 2021, before the goal of 34 patients, depending on the outcomes of a scheduled, prespecified interim research performed to verify the final sample size, and following input from statisticians, principal investigators, payer advisors, and Health Economics and Outcomes Research (HEOR) experts. The very statistically substantial decrease in 30-day heart failure-related expenses reported in patients who took FUROSCIX in the interim analysis led to this conclusion. Based on seven factors linked with hospitalization, the final analysis comprised 24 patients treated with FUROSCIX and 66 matched comparators.
- The FUROSCIX group was shown to have a $17,753 mean difference in heart failure-related expenditures between the two groups, with a p-value of p0.0001 (95 percent CI: -$23,660, -$11,846), preferring the FUROSCIX group.
- The difference in expenses was largely due to the cost of hospitalization. All individuals (24/24) who were recruited in the trial and administered FUROSCIX did not require an initial heart failure hospitalization, and all but one (95.8%) stayed out of the hospital for heart failure for the following 30-day period, as per protocol.
- In the comparison group, all of the patients were admitted to the hospital at the outset, and 10.6% experienced a heart failure-related readmission.
- Infusion site discomfort, bruising, and dizziness were the most prevalent side effects with FUROSCIX, although no major side effects were reported.